Reviewing INVO Fertility (NASDAQ:IVF) and Minerva Surgical (NASDAQ:UTRS)

Minerva Surgical (NASDAQ:UTRS) and INVO Fertility (NASDAQ:IVF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Minerva Surgical and INVO Fertility’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Minerva Surgical	N/A	N/A	N/A
INVO Fertility	-417.02%	N/A	-92.42%

Insider and Institutional Ownership

12.0% of INVO Fertility shares are owned by institutional investors. 8.5% of Minerva Surgical shares are owned by company insiders. Comparatively, 0.7% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Minerva Surgical and INVO Fertility, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Surgical	0	0	0	0	0.00
INVO Fertility	1	0	0	1	2.50

INVO Fertility has a consensus price target of $4.00, indicating a potential upside of 263.64%. Given INVO Fertility’s stronger consensus rating and higher possible upside, analysts plainly believe INVO Fertility is more favorable than Minerva Surgical.

Risk & Volatility

Minerva Surgical has a beta of 2.85, indicating that its stock price is 185% more volatile than the S&P 500. Comparatively, INVO Fertility has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500.

Valuation and Earnings

This table compares Minerva Surgical and INVO Fertility”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Surgical	$51.69 million	0.00	-$34.11 million	($8.21)	N/A
INVO Fertility	$6.94 million	0.38	-$9.10 million	($630.30)	0.00

INVO Fertility has lower revenue, but higher earnings than Minerva Surgical. INVO Fertility is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Minerva Surgical beats INVO Fertility on 7 of the 12 factors compared between the two stocks.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.